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ing the linear-quadratic model ratios): V45.4/ (assuming the previous<50%, V54.5 < 35%, V59.0 < 25%, V63.6 < 20%, V68.2 < 50%
for rectum; V59.0 < 50%, V63.6 < 35%, V68.2 < 25%, V72.7 < 15% for bladder; Dmax<45.4Gy for femoral heads; Dmean<45.4Gy for
penile bulb. Valid singleVMATarcplans are generatedby theTPS. Target volumespreserve theoptimalhomogeneity andcoverage,
as well as OARs maintain their dose–volume parameters under those imposed by QUANTEC: 3.1)%, ±4.0)%, V63.6 = (6.5±4.4)%,
V59.0 = (8.9±5.9)%, V54.5 = (11.7±V45.4 = (20.3 6.5)%,±7.3)%, V63.6 = (9.5±2.4)% for rectum; V59.0 = (12.2±V68.2 = (4.1 4.6)Gy for
femoral±4.0)% for bladder; Dmax= (35.3±5.6)%, V72.7 = (2.7±V68.2 = (6.5 3.7) Gy for penile bulb. Mean treatment time is 310±43
s.±heads; Dmean= (42.3 VMAT in conjunction with IGRT techniques are powerful tools to cover a hypofractionated prostate
cancer treatment program. It is possible to generate optimal plans to treat target volumes as well as to accomplish QUANTEC
constraints. VMAT treatment technique allows the delivery of the treatment in a single arc, with a signiﬁcant reduction in
treatment time.
http://dx.doi.org/10.1016/j.rpor.2013.03.606
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Introduction. The National Radiotherapy Advisory Group (NRAG) of the U.K. recommended that 24% of all radical fractions (32%
of patients) should be delivered with inverse planned IMRT as target for quality radiotherapy care indicator.1
Objective. To analyse the inverse planned IMRT (IP-IMRT) pattern in our center and compare the results to the NRAG recommen-
dations.
Patients & methods. The radiation oncology unit at Alcazar de San Juan covers a population of 203.233 in-habitants censored in
2011. From Jan to Dec 2011 a total of 344 patients were referred for radiation therapy, 106 of these with palliative intent and were
excluded as IP-MRT was not used for palliation.
Results. 36.9% of patients (88 out of 238) received IP-IMRT with radical intent (deﬁne as exclusive & pre or postoperative radiothe-
rapy), accounting for 31.7% of the total number of fractions administered. The technique used was hypofractionated SIB-IMRT in
71.5% of pts and a standard fraction one phase IMRT in 27.3%. According to primary tumor localization the IP-IMRT distribution
was: Prostate 42%, rectal cancer 32% (SIB-IMRT dose escalation study), HNC 15%, Gynecologic cancers 8%. The IMRT use by tumor
site was: Proste 100%, Rectal 82%, HNC 76%, Gynecol 77%. Distribution by treatment intention was as follows: RT only 34.5%,
preoperative 32%, postoperative 23%, cancer local relapse 11%.
Conclusion. Use of IP-IMRT in our center is quite similar to the NRAG recommendations and greater than the 9.9% (8.5% IP-
IMRT+1.4%VMAT) of a recent survey in theUK2 or the 6.2%use in France.3 This benchmarking study allowsus future comparisons
in changing scenarios as reimbursement modiﬁcations or economical constraints.
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Purpose. Keloid represents a signiﬁcant bother for patients and a therapeutic challenge. We present adjuvance with electron
therapy after surgical excision with curative intention.
Materials and methods. Since May – 2007, we treated 20 keloids in 19 patients. Mean age was 38.5 years (interval 16–80). Twelve
females and 8 males were irradiated with a maximum of 4h after surgery. The radiotherapy was delivered using a Clinac 2100
(Varian MS-Palo Alto). Beam energy was 6MeV, with a 4-mm thick aluminum foil 4-mm thick covering the end of the electron
applicator, used as a spoiler. Doses of 15Gy in 5 fractions of 300 cGy/d. were delivered. A 0.5 cm margin around the surgery
excision was included within the treatment ﬁeld, taking account that a thin lead mold should be placed around the scar on the
skin, at least 1 cm inside the optical ﬁeld in order to reduce the beam penumbra. To evaluate results and impact a photograph
was taken before surgery and at the beginning of therapy, and also every year during the follow up (follow-up interval: 4–68
months).
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Results. The most frequent keloid site was ear lobe (n: 10). Three cases were lost and excluded during the follow up. Response to
therapy was shown in 13 cases (76.5%).
Complete response. 9 (53%), Hypertrophic scars: 4, and relapses: 4 (23.5%, mean time: 1 year). After 2 years of follow up, 12 cases
continued as responders (90.3%), 9 cases (69.3%) after 3 years and after 4 years, 8 (61.5%) are still in response. Consequences were
pain and pruritus in 5 patients (29.4%).
Conclusion. Post-excision radiotherapy seems to be an optimum technique in handling keloids. However, electron therapy using
a spoiler needs to be further evaluated in practice. Our results seem to be similar to those obtained with other techniques, such
a Brachytherapy or superﬁcial X-ray.
http://dx.doi.org/10.1016/j.rpor.2013.03.608
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Introduction. Volumetric Modulated Arc Therapy is the last generation of arch dynamic therapy, a technology that allows better
dose conformation, signiﬁcant reduction of treatment time, improvement of patient comfort, reduce the risk of patientmovement
during treatment and reduce the dose received by the organs at risk.
Objective. The purpose of this paper is to present the case of a bilateral ductal invasive carcinoma treated with adjuvant radio-
therapy using VMAT in order to demonstrate its dosimetric advantages.
Materials and methods. The patient is a 62 year old woman diagnosed in April 2011 with Bilateral Ductal Invasive Breast Carcinoma,
cT4 cN1 M0 (Stage IIIB). The patient receives neoadjuvant chemotherapy (Adriamicine-Ciclofosfamide×4, followed by weekly
Paclitaxel×12), followed by a bilateral radical mastectomy and axillary lymph node resection. After that, the woman was sent
to our department to receive adjuvant radiotherapy. Given the characteristics of the target volume, radiotherapy planning with
VMAT technique was chosen in order to reduce the dose received by the organs at risk.
Results. Our PTV was both chest walls and bilateral axillary and supraclavicular lymph node chains. The total dose was 50Gy
delivered in 25 fractions with a daily dose of 200 cGy. Planning was carried out using Monaco 2.03 with an full arch, 154 segments
and 737.24 monitor units. In ﬁgure 1 shows the Dose-Volume histogram, the isodoses in an axial, coronal and 3D reconstruction
and the isodose of 20Gy. Table 1 shows the mean dose to the PTVs and the organs at risk. PTV right chest wall (Doses mean
“Dm”: 50.80Gy); PTV left chest wall (Dm: 51.06Gy); PTV right node (Dm: 50.68Gy); PTV left node (Dm: 50.78Gy) and mean dose in
the most important organs at risk: Heart, (Dm: 12.94Gy and V20: 17.82Gy); right lung, (Dm: 11.96Gy and V20: 18.75Gy) and left
lung, (Dm: 12.08Gy and V20: 19.33Gy). Treatment was carried out using an Elekta Synergy linear accelerator.
Conclusion. Using VMAT, we can administer our planned dose to large PTVs (in this case both chest walls, axillary and supracla-
vicular chains) and exclude organs at risk (heart and lungs) from the dose of 20Gy.
http://dx.doi.org/10.1016/j.rpor.2013.03.609
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Introduction.Weknowobjectivewaysof determining the locationof the radiotherapy treatment isocenter (Image-GuidedRadiation
Therapy), but in many hospitals this is done through portal imaging (2D–2D) supervised by specialists. Without the aid of these
technological means, we can question the inﬂuence exerted by the specialists’ subjectivity on the correct placement of the
isocenter.
Objectives. Observe whether there is a signiﬁcant inﬂuence on the coordinate shifts performed by different specialists for different
tumor sites.
Methods. We studied 552 patients treated with a Siemens Primus linear accelerator. The corrections performed on the treatment
isocenter were analyzed in relation to the position established in the planning stage. These corrections may vary in subsequent
days of treatment giving us a history of not only the variability inherent to the conditions of the patients but also of the variability
due to the degree of subjectivity of the radiation oncologist. Corrections were made based on the realization of portal imaging
tests within the ﬁrst three days of treatment, and then on a weekly basis. We calculated corrections in each of the Cartesian axes
(Dx, Dy and Dz) made for each patient. We also analyzed the maximum coordinate shifts. After grouping patients by pathology
and radiation oncologist, we performed a statistical analysis to test for signiﬁcant differences among different specialists in
determining the isocenter.
